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Peer Review Plan for CDC Opioid 
Prescribing Guidelines for Chronic Pain 
Title: CDC Opioid Prescribing Guidelines for Chronic Pain
Subject of Planned Report:  The guidelines will provide clinical practice 
recommendations on the prescribing of opioids for treating chronic pain based on the 
best available evidence and expert opinion. The guidelines are intended for primary 
care providers (e.g., family practitioners, internists) who are treating patients for 
chronic pain in outpatient settings. Primary care providers account for the greatest 
number of opioid prescriptions compared to other specialists (e.g., surgeons, dentists, 
emergency physicians). Some of the recommendations may be relevant for acute care 
settings, but use in these settings is not the focus of the guidelines. The 
recommendations are also not intended for guiding medication-assisted treatment for 
substance use disorders. The guidelines apply to patients > 18 years with chronic pain 
(i.e., pain lasting longer than 3 months or past the time of normal tissue healing) 
outside of end-of-life care (e.g., in hospice). Patients include those with and without a 
current or previous diagnosis of cancer. Patients may or may not have a history of 
substance use disorder. Special populations (e.g. older adults, pregnant women) will 
be addressed in supporting text when relevant.
Purpose of Planned Report:  The purpose of the guidelines is to provide 
recommendations for the prescribing of opioid pain relievers. The primary focus will be 
on the use of opioids in treating chronic pain. While the guidelines will not focus broadly 
on pain management, opioid use will be framed in the context of pain management 
strategies (including non-opioid pain medication, cognitive-behavioral therapy, physical 
therapy, interventional treatments, and multi-modal pain treatment). The guidelines will 
outline strategies for effective and safe use of opioids when evidence demonstrates their 
benefits outweigh their risks. Improving the way opioids are prescribed through clinical 
practice guidelines can ensure patients have access to safe, effective treatment while 
reducing the number of people who experience substance use disorder or overdose 
related to these drugs.
Type of Dissemination: Influential Scientific Information
Timing of Review (including deferrals): September 2015 – December 2015
Type of Review (panel, individual or alternative procedure): Individual 
Opportunities for the Public to Comment (how and when): CDC has 
developed a tiered approach to stakeholder involvement. In the first phase of guideline 
development, during a closed panel meeting in June, 2015, a Core Expert Group (CEG) 
will consult and provide input on recommendation statements drafted by CDC to be 
included in the CDC Opioid Prescribing Guidelines. The CEG includes a limited number 
of primary care professional society representatives, subject matter experts, state agency 
representatives, and an expert in guideline development methodology. At the panel 
meeting, members will review the evidence related to the benefits and harms of opioid 
use for chronic pain, discuss patient values and preferences and health system costs, and 
provide individual consultation on draft recommendations. In the second phase of 
guideline development, a Stakeholder Review Group (SRG) that includes a larger group 
of interested parties will be responsible for reviewing the full draft of CDC guidelines 
and providing comments to improve the specificity, applicability, and implementability 
of the recommendations. In this group, there is representation from professional 
organizations that represent specialties by which opioids are commonly prescribed (e.g., 
internal medicine, obstetrics and gynecology, geriatrics, pain medicine, physical 
medicine and rehabilitation, and pediatrics). The group also includes representation 
from community stakeholders and advocacy organizations (e.g., pain management 
societies; societies focused on responsible opioid prescribing). In the final phase of the 
guideline development process, public engagement will be solicited through a webinar. 
This webinar will allow for broad public input on the guidelines and for CDC to consider 
public perspectives. Throughout the guideline development process, federal partners 
who have expressed an interest in opioid prescribing guidelines will be engaged and may 
provide input.  
Peer Reviewers Provided with Public Comments before the Review: 
Comments from peer reviewers will be obtained simultaneously with comments from the 
stakeholder review group and the public. Concurrent review is required to allow for rapid 
publication of the guidelines to address an urgent public health need. 
Anticipated Number of Reviewers:  3 
Primary Disciplines or Expertise:  Peer reviewers have been selected based on 
expertise and diversity of scientific viewpoints, while addressing conflict of interest 
concerns and ensuring independence from the guideline development process. Peer 
reviewers were selected who have high scientific standing; appropriate academic 
training and relevant experience; and proven scientific excellence in opioid prescribing, 
addiction, substance use disorder treatment, and pain management. 
Reviewers Selected by (agency or designated outside organization): 
Centers for Disease Control and Prevention (CDC) 
Public Nominations Requested for Reviewers:  No 
Charge to Peer Reviewers: The document that you will review is a draft of the 
guidelines document entitled “CDC Opioid Prescribing Guidelines, 2016.” The final 
recommendations will be posted on the website of the National Center for Injury 
Prevention and Control, Centers for Disease Control and Prevention: http://
www.cdc.gov/drugoverdose/index.html. We request your expert opinion on several 
issues, in particular:  
• The reasonableness of the recommendations, and the strength of the recommendations,
based on evidence and expert opinion
• The clarity with which scientific uncertainties are identified
• The rationale, importance, clarity, and ease of implementation of the recommendations
At a later time, CDC will publicly post any comments you make (without 
attribution) and a summary of the comments from the public engagement webinar
with a response on the NCIPC Peer Review Agenda website: http://
www.cdc.gov/injury/fundedprograms/peerReview.html.
Peer Reviewers: 
Jeanmarie Perrone, MD 
Professor of Emergency Medicine, Hospital of the University of Pennsylvania 
Director, Division of Medical Toxicology, Department of Emergency Medicine 
University of Pennsylvania 
Expertise: medication safety, emergency department prescribing, substance misuse, use 
of prescription drug monitoring programs, toxicology, provider education 
Matthew J. Bair, MD, MS 
Associate Professor of Medicine 
Indiana University School of Medicine 
Expertise: pain management, geriatrics, non-pharmacologic treatments, mental health, 
veterans’ health 
David Tauben, MD 
Chief, Pain Medicine  
Clinical Associate Professor, Department of Anesthesia and Pain Medicine 
Department of Medicine Division of General Internal Medicine 
University of Washington 
Expertise: medical education, primary care, pain management 
Additional elements to be added to the public posting as they become available: 
• Peer reviewer and public comments
• CDC’s response to peer review and public comments
